165 results found.

Healthy Clinical Trial using BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2)..
BI 655075; Placebo to dose; Placebo to BI 655075; dabigatran

Healthy Volunteers Clinical Trial using Placebo; GFT505; Moxifloxacin 400 mg

Genfit - Recruiting 18 years to 45 years.
- A Two-part Phase I Study Composed of a Randomized, Double-blind, 4-parallel Group Study to Evaluate the Effect of Multiple Oral Doses of GFT505 on the QT/QTc Interval Compared to Placebo With Moxifloxacin (400 mg in Single Oral Dose) as a Positive Control, in Healthy Male and Female Volunteers, Preceded by a Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define the Supra-therapeutic GFT505 Dose in a Multiple Dosing Regimen..
Placebo; GFT505; Moxifloxacin 400 mg

Healthy, no Evidence of Disease Clinical Trial using retinoid 9cUAB30; placebo; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Phase I Dose-escalation Study of the Novel Retinoid 9cUAB30.
retinoid 9cUAB30; placebo; laboratory biomarker analysis; pharmacological study

Healthy Volunteers Clinical Trial using Pomegranate Juice; Placebo

University of California, Los Angeles - Recruiting 50 years to 75 years.
- Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging.
Pomegranate Juice; Placebo

Inflammatory Disease, Autoimmune Disease, Immunologic Disease, or Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols.

Hereditary Angioedema (HAE) Clinical Trial using Icatibant (30 mg)

Shire Development LLC - Recruiting 18 years to 55 years.
- An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers.
Icatibant (30 mg)

Healthy Volunteers Clinical Trial using NCTX (PEGylated Liposomal Iodixanol Injection); Saline Placebo

Marval Pharma Ltd. - Recruiting 18 years to 55 years.
- Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers.
NCTX (PEGylated Liposomal Iodixanol Injection); Saline Placebo

Healthy Clinical Trial using 0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Subjects.
0.15 mg PF-06649751; 0.5 mg PF-06649751; 1.5 mg PF-06649751; 1.0 mg PF-06649751; TBD mg PF-06649751

Healthy Clinical Trial using Placebo to BI 1026706; Pregabalin; BI 1026706; Celecoxib

Boehringer Ingelheim - Recruiting 18 years to 55 years.
- Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study).
Placebo to BI 1026706; Pregabalin; BI 1026706; Celecoxib

Arthritis, Rheumatoid, or Healthy Clinical Trial using BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Boehringer Ingelheim - Recruiting 18 years to 70 years.
- A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy.
BI 655064 medium dose; BI 655064 high dose; Placebo; BI 655064 low dose

Healthy Clinical Trial using BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Boehringer Ingelheim - Recruiting 18 years to 50 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design).
BI 1181181; BI 1181181, R; BI 1181181, T2; Placebo to BI 1181181; BI 1181181, T1

Healthy Clinical Trial using BI 113608; Placebo

Boehringer Ingelheim - Recruiting 20 years to 45 years.
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups).
BI 113608; Placebo

Healthy Clinical Trial using BI 1034020; Placebo to BI 1034020

Boehringer Ingelheim - Recruiting 18 years to 40 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study).
BI 1034020; Placebo to BI 1034020

Healthy Clinical Trial using Dabigatran etexilate

Boehringer Ingelheim - Recruiting 18 years to 55 years.
- Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study).
Dabigatran etexilate

Healthy Volunteers Clinical Trial using JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Janssen Cilag N.V./S.A. - Recruiting 18 years to 65 years.
- A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects.
JNJ-38877618: Part 1a; JNJ-38877618: Part 1b; JNJ-38877618: Part 1c (optional); JNJ-38877618: Part 2; JNJ-38877618: Part 3; JNJ-38877618: Part 4 (optional); Placebo: Parts 1a, 2, 3, and 4 (optional)

Healthy Clinical Trial using Tolcapone; Placebo

University of Zurich - Recruiting 20 years to 30 years.
- A Randomized, Double-blind, Placebo-controlled Examination of the Effects of Tolcapone (TASMAR) on Vigilance in Healthy Volunteers After Sleep Deprivation.
Tolcapone; Placebo

Healthy Volunteers Clinical Trial using LY2605541; Insulin Lispro

Eli Lilly and Company - Recruiting 21 years to 65 years.
- A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects.
LY2605541; Insulin Lispro

Healthy Clinical Trial using Canagliflozin; Dapagliflozin

Janssen-Cilag International NV - Recruiting 18 years to 55 years.
- A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects.
Canagliflozin; Dapagliflozin

Healthy Volunteers and Asthma Clinical Trial using CNTO 3157 (healthy participants); Placebo (healthy participants); CNTO 3157 (asthmatic patients); Placebo (asthmatic patients); HRV-16

Janssen Research & Development, LLC - Recruiting 18 years to 65 years.
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16.
CNTO 3157 (healthy participants); Placebo (healthy participants); CNTO 3157 (asthmatic patients); Placebo (asthmatic patients); HRV-16

Healthy Volunteer Clinical Trial using ipatasertib (Tablet); ipatasertib (Capsule)

Genentech - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects.
ipatasertib (Tablet); ipatasertib (Capsule)

Alzheimer's Disease Clinical Trial using ITI-007; Placebo

Intra-Cellular Therapies, Inc. - Recruiting 65 years or older.
- A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia..
ITI-007; Placebo

Stage III Non-small Cell Lung Cancer Clinical Trial using 1 MRI scan

UMC Utrecht - Recruiting 18 years or older.
- MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients.
1 MRI scan

Healthy, or HIV Clinical Trial using 1 mg/kg, single dose IV administration of 3BNC117; 3 mg/kg, single dose IV administration of 3BNC117; 10 mg/kg, single dose IV administration of 3BNC117

Rockefeller University - Recruiting 18 years to 65 years.
- A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers.
1 mg/kg, single dose IV administration of 3BNC117; 3 mg/kg, single dose IV administration of 3BNC117; 10 mg/kg, single dose IV administration of 3BNC117

Healthy Clinical Trial using JNJ-42165279 (100 mg); Placebo

Janssen Research & Development, LLC - Recruiting 18 years to 45 years.
- The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects.
JNJ-42165279 (100 mg); Placebo

Healthy Clinical Trial using 3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

Pfizer - Recruiting 18 years to 55 years.
- Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects.
3 mg PF-06412562; 10 mg PF-06412562; 25 mg PF-06412562; PF-06412562 TBD mg

COPD, or Healthy Subjects Clinical Trial using AZD7624; Placebo to match

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD.
AZD7624; Placebo to match

Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lu Clinical Trial using Skin biopsy; Blood collection; Urine collection

Janssen Research & Development, LLC - Recruiting 18 years to 70 years.
- Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers.
Skin biopsy; Blood collection; Urine collection

Healthy Volunteers Clinical Trial using LY2835219

Eli Lilly and Company - Recruiting 18 years to 65 years.
- Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects.
LY2835219

Physiology Kidney Tubules Receptors, G-Protein-Coupled Clinical Trial using Meat and vegetable diet

Centre Hospitalier Universitaire Vaudois - Recruiting 18 years to 44 years.
- Effect of a Meat Versus Vegetarian Diet in 12 Healthy Volunteers on the Excretion of Alpha-ketoglutarate Measured in 24-hours Urine.
Meat and vegetable diet

Healthy Volunteer Clinical Trial using tocilizumab [RoActemra/Actemra]; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects.
tocilizumab [RoActemra/Actemra]; placebo

Healthy Volunteer Clinical Trial using GDC-0032

Genentech - Recruiting 18 years to 55 years.
- A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects.
GDC-0032

Solid Tumours Clinical Trial using selumetinib; rifampicin

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years.
selumetinib; rifampicin

Healthy Clinical Trial using PF-05230907; Placebo for PF-05230907

Pfizer - Recruiting 18 years to 35 years.
- A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers.
PF-05230907; Placebo for PF-05230907

Analgesia, or Antihyperalgesia Clinical Trial using Melatonin 10 mg; Melatonin 100 mg; Placebo

Herlev Hospital - Recruiting 20 years to 40 years.
- The Analgesic Effects of Melatonin: A Randomized, Placebo-controlled, Double-blinded Study on Healthy Volunteers.
Melatonin 10 mg; Melatonin 100 mg; Placebo

Influenza Clinical Trial using CT-P27; Placebo

Celltrion - Recruiting 18 years to 45 years.
- A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model.
CT-P27; Placebo

Healthy Clinical Trial using Methylphenidate 20 mg tablet given once by mouth; modafinil 200mg tablet given once by mouth; caffein 200mg tablet given once by mouth; placebo

Charite University, Berlin, Germany - Recruiting 18 years to 35 years.
- Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study.
Methylphenidate 20 mg tablet given once by mouth; modafinil 200mg tablet given once by mouth; caffein 200mg tablet given once by mouth; placebo

Uncontrolled and Persistent Asthma Clinical Trial using Phase IIb formulation; Putative phase III formulation; Slow dissolution variant 1; Slow dissolution variant 2; Test treatment E

AstraZeneca - Recruiting 18 years to 50 years.
- An Open-label, Single Centre Relative Bioavailability Study With an Adaptive Design Comparing up to 5 Solid Oral AZD5069 Formulations After Single Dose Administration to Healthy Volunteers.
Phase IIb formulation; Putative phase III formulation; Slow dissolution variant 1; Slow dissolution variant 2; Test treatment E

HIV, Atrial Fibrillation, or Venous Thromboembolism Clinical Trial using Ritonavir; Cobicistat

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers.
Ritonavir; Cobicistat

Influenza A Clinical Trial using Vaccine FP-01.1; Placebo; Virus Challenge

Immune Targeting Systems Ltd - Recruiting 18 years to 45 years.
- A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (Vaccine FP-01.1) in Healthy Volunteers Following Virus Challenge.
Vaccine FP-01.1; Placebo; Virus Challenge

Healthy Clinical Trial using BIIB061; Placebo; 14C-BIIB061

Biogen Idec - Recruiting 20 years to 55 years.
- A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect.
BIIB061; Placebo; 14C-BIIB061

Alzheimer's Disease Clinical Trial using BNC

National Institutes of Health Clinical Center (CC) - Recruiting 55 years or older.
- Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers.
BNC

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Normal Volunteers.

Movement Disorder, Tourette Syndrome, or Healthy Volunteer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders.

Healthy Volunteers Clinical Trial using Sucralose

National Institutes of Health Clinical Center (CC) - Recruiting 6 years to 45 years.
- Metabolic Effects of Non-Nutritive Sweeteners.
Sucralose

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years or older.
- Collection of Blood, Bone Marrow, Skin Biopsies and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols Laboratory Research Studies.

Obesity, or Healthy Volunteers Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 55 years.
- Fat Metabolism and Function Altering Polymorphisms in MC3R.

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Graft vs Host Disease, or Graft-Versus-Host Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Saliva From Healthy Volunteers for Research.

Communication Disorder, Healthy, Stuttering, Tourette Syndrome, o Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 85 years.
- Multimodal Studies of Language Production and Comprehension in Normal Volunteers and Patients With Neurologically-Based Language Impairments.

Healthy, Inflammation, or Vasculitis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 years to 65 years.
- Comparison of Inflammatory Responses in Normal Volunteers and Patients With Abnormal Phagocyte Function Using the Suction Blister Technique.

Graft vs Host Disease, Healthy, or Lymphopenia Clinical Trial using G-CSF

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation.
G-CSF

Healthy Volunteer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies.

Influenza Clinical Trial using AVI-7100 versus placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects.
AVI-7100 versus placebo

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years or older.
- Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers.

Gardasil Vaccine, Stem Cell Transplant, Immunogenicity, Quadrival Clinical Trial using Gardasil

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression.
Gardasil

Immunosuppression, Healthy, or Healthy Subjects Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Effects of Systemically Administered Hydrocortisone on the Human Immunome in Healthy Volunteers.

Autism Spectrum Disorders, Brain Disease, Autism, or Healthy Volu Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Neuroimmune Activation in Austism: Imaging Translocator Protein Using Positron Emission Tomography (PET).

Multiple Sclerosis, or Optic Neuritis Clinical Trial using Mangafodipir (Teslascan)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis.
Mangafodipir (Teslascan)

H5N1 Influenza Clinical Trial using Ad4-H5-VTN vaccination-tonsillar route; Ad4-H5-vaccination-oral route

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 49 years.
- Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers.
Ad4-H5-VTN vaccination-tonsillar route; Ad4-H5-vaccination-oral route

Breast Cancer, Healthy Volunteer, or Prostate Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin.

Gonococcal (GC) Infection Clinical Trial using Part A; Part B; Part C

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Randomized, Placebo-controlled, Single Center Study to Assess the Safety, Tolerability, and Pharmacokinetic of AZD0914 After Oral Administration of Single Doses or Multiple Doses Over 24 Hours and to Assess the Effect of Food in Healthy Adult Volunteers.
Part A; Part B; Part C

Pharmacokinetics,, Open Label,, CAZ-AVI,, CXL,, Effect on Intesti Clinical Trial using CAZ-AVI; CXL

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers..
CAZ-AVI; CXL

Influenza Clinical Trial using MG1109

Green Cross Corporation - Recruiting 18 years to 60 years.
- Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers.
MG1109

Healthy Volunteer Clinical Trial using RO6864018

Hoffmann-La Roche - Recruiting 21 years to 65 years.
- A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6864018 FOLLOWING ORAL ADMINISTRATION IN ASIAN HEALTHY SUBJECTS.
RO6864018

Healthy Volunteers Clinical Trial using CANA/MET XR FDC

Janssen Research & Development, LLC - Recruiting 18 years to 55 years.
- An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects.
CANA/MET XR FDC

Cancer Clinical Trial using GSK2110183 Gelatin Capsule; GSK2110183 IR Tablet

GlaxoSmithKline - Recruiting 18 years to 40 years.
- A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers.
GSK2110183 Gelatin Capsule; GSK2110183 IR Tablet

Hepatitis C Clinical Trial using Peginterferon lambda

Nanogen Pharmaceutical Biotechnology Co., Ltd - Recruiting 18 years to 65 years.
- The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients.
Peginterferon lambda

Healthy Clinical Trial using ARC-520; Placebo

Arrowhead Research Corporation - Recruiting 18 years to 55 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers.
ARC-520; Placebo

Alzheimer's Disease Clinical Trial using AZD3293; Placebo; Moxifloxacin

AstraZeneca - Recruiting 18 years to 55 years.
- A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects.
AZD3293; Placebo; Moxifloxacin

Inhibition on Platelet Aggregation Clinical Trial using Ticagrelor; Clopidogrel; ASA

AstraZeneca - Recruiting 18 years to 50 years.
- A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition.
Ticagrelor; Clopidogrel; ASA

Healthy Volunteers Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 60 years.
- Experienced Breacher Study: Evaluation of the Effects From Chronic Exposure to Low-Level Blast.

Healthy Volunteers Clinical Trial using AKB-6548 (therapeutic dose); AKB-6548 (supratherapeutic dose); Placebo; Moxifloxacin

Akebia Therapeutics - Recruiting 18 years to 55 years.
- A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers.
AKB-6548 (therapeutic dose); AKB-6548 (supratherapeutic dose); Placebo; Moxifloxacin

Renal Impairment, Renal Insufficiency, Kidney Disease, or Kidney Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years to 75 years.
- An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers.
IDN-6556

Healthy Clinical Trial using Crizotinib prototype microsphere 0.529 mg/mg; crizotinib prototype microsphere 0.470 mg/mg; crizotinib prototype microsphere 0.420 mg/mg; crizotinib oral solution; crizotinib prototype microsphere 0.529 mg/mg; crizotinib capsule

Pfizer - Recruiting 18 years to 55 years.
- A Phase 1, Open-label, Crossover Taste And Pharmacokinetic Study In Healthy Adult Volunteers To Evaluate The Palatability And Estimate The Bioavailability Of Three Prototype Formulations Of Crizotinib.
Crizotinib prototype microsphere 0.529 mg/mg; crizotinib prototype microsphere 0.470 mg/mg; crizotinib prototype microsphere 0.420 mg/mg; crizotinib oral solution; crizotinib prototype microsphere 0.529 mg/mg; crizotinib capsule

LPS Challenge, Neutrophils Clinical Trial using AZD7624; Placebo

AstraZeneca - Recruiting 18 years to 55 years.
- A Double Blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood After Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS).
AZD7624; Placebo

Pain, Hyperalgesia, or Central Sensitization Clinical Trial using Carbetocin; Placebo

University Hospital Inselspital, Berne - Recruiting 18 years to 65 years.
- Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers.
Carbetocin; Placebo

Asthma Clinical Trial using RV16UB

Merck Sharp & Dohme Corp. - Recruiting 18 years to 55 years.
- A Dose-Finding and Longitudinal Biomarker Study of Rhinovirus Challenge in Healthy Volunteers and Mild-Moderate Asthmatics to Evaluate the Safety and Use of a Human Rhinovirus Preparation in Developing High Dimensionality Phenotypes ('Handprints') for Asthma.
RV16UB

Acute Respiratory Insufficiency, Chronic Respiratory Insufficienc Clinical Trial using Nebulizer

University Hospital St Luc, Brussels - Recruiting 18 years or older.
- Comparison of Pharmacokinetics of Amikacin Administered by Three Vibrating Mesh Nebulizers in Healthy Volunteers.
Nebulizer

Healthy Volunteers Clinical Trial using REGN1033 (SAR391786); placebo

Regeneron Pharmaceuticals - Recruiting 60 years or older.
- .
REGN1033 (SAR391786); placebo

Stroke Clinical Trial using JPI-289; Placebo

Jeil Pharmaceutical Co., Ltd. - Recruiting 19 years to 55 years.
- A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects..
JPI-289; Placebo

Healthy Volunteers Clinical Trial using RG-HRV16; Placebo

University of Wisconsin, Madison - Recruiting 18 years to 50 years.
- A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers.
RG-HRV16; Placebo

Healthy Volunteer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION.

Healthy Volunteers, or Pharmacologic Action Clinical Trial using AZD3293 oral solution; AZD3293 tablet formulation A; AZD3293 tablet formulation B

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects.
AZD3293 oral solution; AZD3293 tablet formulation A; AZD3293 tablet formulation B

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial using AZD4721; Placebo; AZD5069

AstraZeneca - Recruiting 18 years to 50 years.
- A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days.
AZD4721; Placebo; AZD5069

Healthy Clinical Trial using Adductor canal block with lidocaine 1%; Lidocaine

Rigshospitalet, Denmark - Recruiting 18 years to 30 years.
- An Estimate of the ED95 of Lidocaine 1.0% for Filling the Adductor Canal When Placing an Adductor Canal Block in Healthy Volunteers.
Adductor canal block with lidocaine 1%; Lidocaine

Healthy Clinical Trial using BI 695501; adalimumab-EU source; adalimumab-US source

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 55 years.
- Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study.
BI 695501; adalimumab-EU source; adalimumab-US source

Blood Donation, Cellular Therapies, or Tissue Procurement Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood From Healthy Volunteers and Clinical Research Subjects for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products.

Healthy Subjects, or Hepatitis B Clinical Trial using Hepatitis B Vaccine (Recombinant)

Rockefeller University - Recruiting 18 years to 60 years.
- Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers.
Hepatitis B Vaccine (Recombinant)

Osteoporosis, With or Without Treatment, Bisphosphonate Treatment Clinical Trial

University of Pennsylvania - Recruiting 18 years or older.
- Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects.

Solid Tumours Clinical Trial using selumetinib (oral)

AstraZeneca - Recruiting 18 years to 45 years.
- A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years.
selumetinib (oral)

Part 1 - Healthy Volunteers, or Part 2 - Patients With Hypertensi Clinical Trial using LFF269; Placebo to LFF269

Novartis - Recruiting 18 years to 80 years.
- A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects.
LFF269; Placebo to LFF269

Healthy Clinical Trial using food consumption

Imperial College London - Recruiting 18 years to 65 years.
- Glycaemic Index Testing of Carbohydrate Containing Foods Using a Standardised Method.
food consumption

Healthy Volunteer Clinical Trial using MHAA549A; Placebo; oseltamivir [Tamiflu]

Genentech - Recruiting 18 years to 45 years.
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model.
MHAA549A; Placebo; oseltamivir [Tamiflu]

Cytomegalovirus Infection, or Healthy, no Evidence of Disease Clinical Trial using multi-CMV epitope modified vaccinia Ankara vaccine; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 50 years.
- Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia.
multi-CMV epitope modified vaccinia Ankara vaccine; laboratory biomarker analysis

Healthy Volunteer Clinical Trial using RO4995819

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects.
RO4995819

Healthy Volunteer Clinical Trial using Posaconozole; RO5424802

Hoffmann-La Roche - Recruiting 18 years to 55 years.
- An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects.
Posaconozole; RO5424802

Healthy Volunteer Clinical Trial using RO6870868; placebo

Hoffmann-La Roche - Recruiting 18 years to 65 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868.
RO6870868; placebo

Healthy Volunteer Clinical Trial using RO5545965; placebo

Hoffmann-La Roche - Recruiting 18 years to 64 years.
- A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects..
RO5545965; placebo

Overweight, Obesity, Type 2 Diabetes Mellitus Clinical Trial using AZP-531

Aliz‚ Pharma - Recruiting 18 years to 50 years.
- A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus.
AZP-531

Ebola Virus Infection Clinical Trial using TKM-100802 for Injection; Placebo

Tekmira Pharmaceuticals Corporation - Recruiting 18 years to 50 years.
- A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers.
TKM-100802 for Injection; Placebo

Submental Fat, Safety, Efficacy, or Healthy Volunteers Clinical Trial using ATX-101; Placebo

Kythera Biopharmaceuticals - Recruiting 18 years to 65 years.
- A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 or CR-SMFRS Grade 4.
ATX-101; Placebo

Arthritis, Rheumatoid Clinical Trial using CHR-5154; Placebo

GlaxoSmithKline - Recruiting 18 years to 45 years.
- A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers.
CHR-5154; Placebo

Healthy Clinical Trial using Large volume blood draw

Pfizer - Recruiting 18 years to 70 years.
- Blood Collection in Healthy Adult Volunteers to Obtain Serum for Use in Opsonophagocytic-Assay Development.
Large volume blood draw

Healthy Japanese Young and Elderly Male and Non-fertile Female Vo Clinical Trial using AZD3293; Placebo

AstraZeneca - Recruiting 20 years to 80 years.
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Healthy Japanese Male and Non-Fertile Female Volunteers Including Elderly.
AZD3293; Placebo

Healthy Clinical Trial using BI 655064; Placebo

Boehringer Ingelheim Pharmaceuticals - Recruiting 20 years to 45 years.
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study).
BI 655064; Placebo

Healthy, or Salivary Gland Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Salivary Evaluation in Healthy Volunteers.

Healthy Volunteers, or Pharmacologic Action Clinical Trial using Group 1 AZD3293; Group 2 AZD3293; Group 3 AZD3293; Group 1 Itraconazole; Group 2 Diltiazem; Group 3 Midazolam

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers.
Group 1 AZD3293; Group 2 AZD3293; Group 3 AZD3293; Group 1 Itraconazole; Group 2 Diltiazem; Group 3 Midazolam

Healthy Subjects Clinical Trial using Blood Collection

Pfizer - Recruiting 18 years to 64 years.
- Blood Collection in Healthy Adult Volunteers to Obtain Serum for Use in Serum Bactericidal Activity Assay Development.
Blood Collection

Healthy Volunteers Clinical Trial using RDC5

Chronos Therapeutics Ltd - Recruiting 18 years to 55 years.
- A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers.
RDC5

Healthy Volunteer, or HIV Vaccine Clinical Trial using Ad4-mgag; Ad4-EnvC150

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 49 years.
- Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers.
Ad4-mgag; Ad4-EnvC150

Abetalipoproteinemia, Atherosclerosis, Healthy, or Inborn Errors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients.

Rheumatic Diseases, or Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection Of Blood Components Using Apheresis From Patients With Rheumatic Diseases and Healthy Volunteers.

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Peripheral Blood Stem Cell Collection From Adult Volunteers.

Healthy, or Skin Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Acquisition of Blood and Skin Samples From Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases.

Healthy, or Helminthiasis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 65 years.
- Langherhans' Cell Function and Inflammatory Responses in Skin of Volunteers Using the Suction Blister Technique.

Healthy, Pituitary Disease, or Thyroid Disease Clinical Trial using TRH (Thyrotropin Releasing Hormone)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities.
TRH (Thyrotropin Releasing Hormone)

Bone Marrow, Bone Marrow Stromal Cells, Mesenchymal Stem Cells, o Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products.

Sarcopenia, Frailty, or Aging Clinical Trial using Muscle Biopsy

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Muscle Biopsies in Healthy Volunteers: a Pilot Study.
Muscle Biopsy

Healthy Volunteer Clinical Trial using Ad4-H5-Vtn

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 49 years.
- Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers.
Ad4-H5-Vtn

Healthy Volunteers Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Thyroid Hormone-Induced Lipolysis: An In Vivo Microdialysis Study.

Hemophilia A, or Hemophilia B Clinical Trial using ALN-AT3SC; Sterile Normal Saline (0.9% NaCl)

Alnylam Pharmaceuticals - Recruiting 18 years to 65 years.
- A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia).
ALN-AT3SC; Sterile Normal Saline (0.9% NaCl)

Focus of Study: Radiolabel Recovery and Survival of RBCs Clinical Trial using Mirasol System for Whole Blood

Terumo BCTbio - Recruiting 18 years or older.
- Inactivation of Whole Blood With Mirasol : Performance in Red Blood Cells in Healthy Volunteers.
Mirasol System for Whole Blood

Healthy Volunteers With and Without Chronic Low Back Pain Clinical Trial using Exercise

Hannover Medical School - Recruiting 18 years to 67 years.
- Effects of a Home-based Exercise Program on Low Back Pain in Employees.
Exercise

Healthy Clinical Trial using PF-05280014; Herceptinr

Pfizer - Recruiting 18 years to 55 years.
- Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 2-Arm, Safety Study Of PF-05280014 And Trastuzumab Sourced From The US Administered To Healthy Male Volunteers.
PF-05280014; Herceptinr

No Condition, or Brain GABA-B Function Clinical Trial using Baclofen 10mg; Baclofen 60mg; placebo

Imperial College London - Recruiting 21 years to 40 years.
- GABA-B Receptor Function in Healthy Volunteers: a Pilot, Double Blind Crossover Study of the Effects of 2 Doses of Baclofen and Placebo on Objective and Subjective Measurements of Brain Function.
Baclofen 10mg; Baclofen 60mg; placebo

Healthy Volunteers Pharmacokinetic Study Clinical Trial using Selumetinib

AstraZeneca - Recruiting 18 years to 55 years.
- A Phase I, Single-centre, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Selumetinib Given Orally in Japanese and Non-Japanese Asian Healthy Male Volunteers.
Selumetinib

Colorectal Cancer, or Healthy, no Evidence of Disease Clinical Trial using linaclotide acetate; placebo; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers.
linaclotide acetate; placebo; pharmacological study; laboratory biomarker analysis

Healthy Volunteers Clinical Trial using LY2969822; Placebo

Eli Lilly and Company - Recruiting 21 years or older.
- A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects.
LY2969822; Placebo

Healthy Clinical Trial using Empagliflozin 2.5 mg; Empagliflozin 10 mg; Metformin 500 mg; Empagliflozin/Metformin FDC

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years to 50 years.
- Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study).
Empagliflozin 2.5 mg; Empagliflozin 10 mg; Metformin 500 mg; Empagliflozin/Metformin FDC

Healthy Clinical Trial using rigosertib

Onconova Therapeutics, Inc. - Recruiting 18 years to 55 years.
- Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers.
rigosertib

Healthy Volunteers Clinical Trial using EVP unflavoured; EVP flavoured; Nicotine inhalator 15mg; Conventional cigarette

Imperial Tobacco Group PLC - Recruiting 21 years to 65 years.
- A Randomised, Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product, a Nicotine Inhalator and a Conventional Cigarette.
EVP unflavoured; EVP flavoured; Nicotine inhalator 15mg; Conventional cigarette

Healthy Clinical Trial using RTA 408 Lotion 0.5%, 1%, 3%; Lotion vehicle/placebo

Reata Pharmaceuticals, Inc. - Recruiting 18 years to 65 years.
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 Lotion in Healthy Volunteers.
RTA 408 Lotion 0.5%, 1%, 3%; Lotion vehicle/placebo

Healthy Volunteers Clinical Trial using E-vapour product; Conventional cigarette

Imperial Tobacco Group PLC - Recruiting 21 years to 65 years.
- A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product.
E-vapour product; Conventional cigarette

Healthy Volunteers Clinical Trial using Esketamine

Janssen Research & Development, LLC - Recruiting 20 years to 55 years.
- An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Subjects.
Esketamine

Healthy Volunteers Clinical Trial using LY3127760; Celecoxib; Placebo

Eli Lilly and Company - Recruiting 18 years to 65 years.
- A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects.
LY3127760; Celecoxib; Placebo

Healthy Volunteers Clinical Trial using Ecologic 825/scFOS; Placebo

Maastricht University Medical Center - Recruiting 18 years to 65 years.
- The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function.
Ecologic 825/scFOS; Placebo

Alzheimer's Disease Clinical Trial using florbetapir F 18; 18F-AV-1451

Avid Radiopharmaceuticals - Recruiting 20 years or older.
- An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease.
florbetapir F 18; 18F-AV-1451

Platelet Function Test Clinical Trial using Curcuma longa; Angelica sinensis; Siwu Tang; Aspirin

Singapore General Hospital - Recruiting 18 years to 70 years.
- A Randomized, Double Blind, Placebo-controlled Crossover Study on the Effect of Commonly Used Herbal Products on Platelet Function and Coagulation Profile of Healthy Volunteers.
Curcuma longa; Angelica sinensis; Siwu Tang; Aspirin

Diabetes Mellitus, Type 2, or Healthy Volunteers Clinical Trial using Dulaglutide; Placebo

Eli Lilly and Company - Recruiting 18 years to 75 years.
- Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM.
Dulaglutide; Placebo

Healthy, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 55 years.
- Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers.

Mood Disorder, or Anxiety Disorder Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 years to 85 years.
- The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers.

HIV Infections Clinical Trial using CN54gp140 mixed with GLA-AF

Imperial College London - Recruiting 18 years to 45 years.
- A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers.
CN54gp140 mixed with GLA-AF

Alopecia Clinical Trial using GI198745 0.1 mg; GI198745 0.5 mg

GlaxoSmithKline - Recruiting 18 years to 65 years.
- An Evaluation of the Bioequivalence of Five 0.1 mg GI198745/Dutasteride Soft Gelatin Capsules Compared to One 0.5 mg GI198745/Dutasteride Gelatin Capsules in Healthy Male Volunteers.
GI198745 0.1 mg; GI198745 0.5 mg

Healthy Volunteers Clinical Trial using POMx; Placebo

University of California, Los Angeles - Recruiting 50 years to 75 years.
- 12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract.
POMx; Placebo

Healthy Volunteers Clinical Trial using [11c] LAAM; Ritonavir; Efavirenz

Washington University School of Medicine - Recruiting 18 years to 50 years.
- Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging.
[11c] LAAM; Ritonavir; Efavirenz

Peripheral Vein Vasodilation Clinical Trial using 50% Nitrous oxide

Columbia University - Recruiting 19 years or older.
- Peripheral Vasodilation in Healthy Adult Volunteers Receiving 50% Nitrous Oxide.
50% Nitrous oxide

Alzheimer's Disease Clinical Trial using [11C]PIB

Johns Hopkins University - Recruiting 18 years to 80 years.
- '[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls'.
[11C]PIB

HIV Infections Clinical Trial using SeV-G(NP) (0.2mL, 2x10^7 CIU); SeV-G(NP) (0.2mL, 2x10^8 CIU); Ad35-GRIN (0.5mL)

International AIDS Vaccine Initiative - Recruiting 18 years to 50 years.
- A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers.
SeV-G(NP) (0.2mL, 2x10^7 CIU); SeV-G(NP) (0.2mL, 2x10^8 CIU); Ad35-GRIN (0.5mL)

Healthy, no Evidence of Disease Clinical Trial using polymorphism analysis; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 35 years to 69 years.
- A Population Based Control Collection for Genetic Studies in East Anglia.
polymorphism analysis; laboratory biomarker analysis; questionnaire administration

Infections, Bacterial Clinical Trial using GSK1322322 Initial fit for purpose tablets; GSK1322322 over granulated tablets; GSK1322322 intended commercial tablets; Placebo tablets; 13C-GSK1322322 stable isotope powder; GSK1322322 for injection; Placebo injection

GlaxoSmithKline - Recruiting 18 years to 65 years.
- A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects.
GSK1322322 Initial fit for purpose tablets; GSK1322322 over granulated tablets; GSK1322322 intended commercial tablets; Placebo tablets; 13C-GSK1322322 stable isotope powder; GSK1322322 for injection; Placebo injection

Healthy Volunteers Clinical Trial using Finasteride; Dutasteride

University of Birmingham - Recruiting 18 years to 65 years.
- An Open Label Study of 5à-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers..
Finasteride; Dutasteride

Healthy, Mood Disorder, Parkinson's Disease, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 3.0 Tesla MRI and Magnetoencephalography.

Healthy Clinical Trial using VVZ-149 Injection; placebo (water for injection)

Vivozon, Inc. - Recruiting 20 years to 45 years.
- A Randomized, Double-blind, Single and Multiple Ascending Dose Escalation, Placebo-controlled Clinical Trial to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection in Healthy Male Volunteers.
VVZ-149 Injection; placebo (water for injection)

Left Ventricular Hypertrophy Clinical Trial using Exercise training, women, marathon

University of California, San Francisco - Recruiting 18 years to 55 years.
- Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism in Healthy Female Volunteers Training for a Marathon.
Exercise training, women, marathon

Gastroesophageal Reflux, or Gastroesophageal Reflux Disease Clinical Trial using PPC-5650; Placebo

Aalborg Universityhospital - Recruiting 20 years to 65 years.
- A Single-center, Randomized, Double-blind, Cross-over Trial in Healthy Volunteers Investigating the Local Efficacy and Safety of a Single Intra-luminal Administration of PPC-5650 on Reflux Pain and Hyperalgesia During Multimodal Stimulation of the Esophagus.
PPC-5650; Placebo

Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Normal Volunteer Scanning on MR.

Healthy Male Volunteers Clinical Trial using micronized fenofibrate 160mg; pitavastatin Ca 2mg; micronized fenofibrate 160mg plus pitavastatin Ca 2mg

Hanlim Pharm. Co., Ltd. - Recruiting 20 years to 55 years.
- Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects.
micronized fenofibrate 160mg; pitavastatin Ca 2mg; micronized fenofibrate 160mg plus pitavastatin Ca 2mg

Psychotropic Drugs Effects Clinical Trial using Zolpidem; Alprazolam; Caffeine; Placebo

Mclean Hospital - Recruiting 21 years to 40 years.
- Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T.
Zolpidem; Alprazolam; Caffeine; Placebo

Healthy Volunteers Clinical Trial using cipralex

RWTH Aachen University - Recruiting 18 years to 60 years.
- Genetic-pharmacological Neuroimaging of the Serotonergic System in Violent Video Games.
cipralex

Healthy Volunteers Clinical Trial using Brocco-sprout homogenate; Alfalfa sprout homogenate

Imperial College London - Recruiting 18 years or older.
- Does Broccoli Sprout Consumption Result in Plasma Sulforaphane Levels That Can Attenuate Leukocyte Activation Ex-vivo in Healthy Human Volunteers?.
Brocco-sprout homogenate; Alfalfa sprout homogenate

Healthy Volunteers Clinical Trial using raltegravir; Placebo

Hospital Clinic of Barcelona - Recruiting 18 years to 45 years.
- Study on the Effects of Raltegravir (Isentressr) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers.
raltegravir; Placebo

Healthy, or Obesity Clinical Trial using Quark RMR; Deltatrac II

Hospices Civils de Lyon - Recruiting 18 years to 60 years.
- Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems) for Measuring Energy Expenditure at Rest and in Dynamic Phase After a Meal in Adult Healthy and Obese Volunteers.
Quark RMR; Deltatrac II

Healthy, or Cancer Clinical Trial using Zen meditation

Hospital Israelita Albert Einstein - Recruiting 18 years to 65 years.
- The Effects of an Intensive Mindfulness Practice (Sesshin) on Neural Systems: an fMRI Evaluation of Healthy Volunteers and Cancer Patients.
Zen meditation

Asthma Clinical Trial using BMEC-1217B

Medigreen Biotechnology Corp. - Recruiting 20 years to 40 years.
- A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Safety Study of BMEC-1217B, in Healthy Volunteers.
BMEC-1217B

Chronic Obstructive Airway Disease, or Healthy Volunteers Clinical Trial using Up to 100ml blood will be taken by venupuncture.

Imperial College London - Recruiting 21 years to 75 years.
- Regulation of the Release of Inflammatory Mediators From Blood Leukocytes: A Comparison of Healthy Subjects, Healthy Smokers and Patients With COPD..
Up to 100ml blood will be taken by venupuncture.